The 2025 Wilson Sonsini E&I Summit Attracts Over 400 Participants
The 2025 Wilson Sonsini E&I Summit Attracts Over 400 Participants […]
First Patient Enrolled in Merit Medical’s PREEMIE Study
Multicenter, prospective study designed to evaluate safety and efficacy of Bloom™ Micro Occluder System for treatment of patent ductus arteriosus in premature infants […]
iVeena Secures $3 Million in Series B-2 Financing to Accelerate Development of IVMED-85 for Myopia
iVeena Secures $3 Million in Series B-2 Financing to Accelerate Development of IVMED-85 for Myopia […]
Altitude Lab Demo Day
As part of BioHive week, Altitude Lab hosted its annual Demo Day. […]
Steve Pacelli Appointed CEO of Epitel, Inc.
Pacelli, A Former Executive of Dexcom, Inc., Will Lead Epitel Into Its Next Phase of Growth […]
Sera Prognostics Announces Pricing of $50 Million Public Offering
Sera Prognostics Announces Pricing of $50 Million Public Offering […]
The Teva Turnaround: Steering a Company Comeback
CEO Richard Francis reflects on Teva’s return to growth during his tenure, and what’s next for the drugmaker in its quest to recapture the heights of old. […]
Craig-Hallum Initiates Myriad Genetics Stock with a Buy Rating
Craig-Hallum Initiates Myriad Genetics Stock with a Buy Rating […]
bioMérieux receives U.S. FDA clearance for the new version of its molecular test targeting causes of gastroenteritis, BIOFIRE® FILMARRAY® Gastrointestinal (GI) Panel Mid
bioMérieux receives U.S. FDA clearance for the new version of its molecular test targeting causes of gastroenteritis, BIOFIRE® FILMARRAY® Gastrointestinal (GI) Panel Mid […]
EVŌQ Nano Secures Strategic Investment From Global Business Leader & Philanthropist Tony Robbins to Advance Next-Generation Antimicrobial Nanoparticle Technology
EVŌQ Nano Secures Strategic Investment From Global Business Leader & Philanthropist Tony Robbins to Advance Next-Generation Antimicrobial Nanoparticle Technology […]
Denali Therapeutics Announces Primary Analysis and Long-Term Follow-Up of Phase 1/2 Study in Hunter Syndrome (MPS II) with Tividenofusp Alfa
Denali Therapeutics Announces Primary Analysis and Long-Term Follow-Up of Phase 1/2 Study in Hunter Syndrome (MPS II) with Tividenofusp Alfa […]
Nelson Labs Leuven Unveils Cutting-Edge Analytical Upgrade for Non-Volatile Extractables & Leachables Screening
Nelson Labs Leuven Unveils Cutting-Edge Analytical Upgrade for Non-Volatile Extractables & Leachables Screening […]